Cold agglutinin disease (CAD) appears to be the most common type of autoimmune hemolytic anemia (AIHA) — a group of autoimmune diseases marked by attacks on red blood cells — that is triggered by COVID-19, according to a review of published studies. Patients developed AIHA about 13 days after…
Read more
“Mike, stop!” I yelled at my boyfriend, now husband, as we crossed an intersection in Auburn, Alabama. “Let me move that turtle out of the way.” A few disgruntled drivers were in cars behind us. As a soft-hearted nature lover, I made everyone wait while I dealt with this more…
Riliprubart (SAR445088), a potential successor to Enjaymo (sutimlimab-jome) as a cold agglutinin disease (CAD) treatment, may achieve therapeutic levels with every-three-month dosing at a fixed dose. That’s according to a study that used modeling tools to analyze available clinical trial data and propose an optimal dosing regimen for…
“You should’ve started writing earlier. Now you’ve wasted the time and won’t get it done by deadline. This is what you always do: You’re always late and disorganized. You really ought to give up. You’re not any good anyway.” That voice in my head is my worst enemy. There’s a…
Nearly half of people without symptoms of cold agglutinin disease (CAD) who undergo a lung transplant test positive for cold agglutinins, the self-reactive antibodies that drive the rare autoimmune condition by targeting red blood cells at low temperatures. That’s according to new data from the first study of its kind…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
